Clomipramine is a tricyclic antidepressant, but the selected Anafranil capsule label identifies treatment of obsessions and compulsions in obsessive-compulsive disorder (OCD). Its information covers potential symptom benefit alongside digestive, alertness, sexual, urinary, and serious safety concerns. These findings explain the product’s evidence, not whether it is suitable for you.

Reading about an existing or proposed prescription can bring two different concerns: what the medicine may help with, and what unwanted effects deserve attention. This article examines one selected FDA record for Anafranil Capsules USP, containing clomipramine hydrochloride for oral use. It does not cover every generic product or establish the latest labeling for your dispensed prescription. The adult OCD studies, counseling information, and evidence gaps each answer different questions. Understanding those differences can make the label less confusing without turning it into a diagnosis, a personal risk prediction, or instructions for changing treatment.

What is clomipramine, and what is Anafranil labeled for?

Anafranil is an oral capsule containing clomipramine hydrochloride, labeled for OCD obsessions and compulsions. MVBH’s explanations of medicine information documents and Medication Guides and serious risks provide context for reading that product-specific indication.

The selected FDA label places clomipramine in the tricyclic antidepressant class. A drug class and a labeled indication are not interchangeable. The word “antidepressant” does not add depression, general anxiety, panic disorder, or insomnia to this record’s indications. Conversely, the absence of an indication here does not, by itself, establish that someone’s prescription is inappropriate.

In general terms, obsessions are recurring, difficult-to-control thoughts, and compulsions are repetitive, excessive behaviors. NIMH’s OCD overview explains that these symptoms can consume time and interfere with daily life. That description is context, not a self-test or confirmation of anyone’s diagnosis.

What do Anafranil’s adult OCD studies establish?

The label reports evidence of OCD symptom improvement in adult placebo-controlled studies. MVBH’s articles on professional medicine information and Medication Guides for serious risks explain the different purposes of these documents. The patient guide does not contain the complete effectiveness evidence.

The adult studies involved people with moderate-to-severe OCD. Participants receiving clomipramine had greater improvement on measures of obsessions and compulsions than those receiving placebo. The label describes changes on the Yale-Brown Obsessive Compulsive Scale and an NIMH OCD scale. These are group findings about measured symptoms, not a promise of a particular personal response, complete recovery, or improvement in every area of life.

The FDA record’s effectiveness section also states that effectiveness beyond ten weeks had not been systematically evaluated in placebo-controlled trials. This describes a boundary of the evidence presented. It is not a maximum treatment duration, proof that longer treatment cannot help, or an instruction to stop. The label places longer-term usefulness within individual professional reevaluation.

Which common clomipramine reactions can affect daily life?

The label describes digestive symptoms, sleepiness, movement-related effects, and other reactions that may affect ordinary activities. MVBH’s resources on reading medicine information and understanding serious-risk documents help distinguish these reports from separate safety warnings.

  • Mouth and digestion: Dry mouth, constipation, and nausea are among the commonly observed complaints. These describe different experiences, rather than one general stomach reaction.
  • Alertness and energy: Sleepiness, dizziness, and fatigue may affect how awake or physically capable someone feels.
  • Movement: Tremor is a reported reaction. Its presence does not measure whether obsessions or compulsions are improving.
  • Sweating: Increased sweating is also reported, separately from digestive and nervous-system complaints.

The Anafranil adverse-reaction and counseling sections describe these reactions and caution that the medicine can impair the mental or physical abilities required for complex or hazardous tasks. Impairment is not the same as feeling therapeutically calmer. It deserves attention independently of symptom benefit.

The label contains several kinds of adverse-event evidence. They should not be read as one uniform list of proven causes or personal probabilities.

Different adverse-event evidence in the selected Anafranil label
Evidence in the Anafranil labelWhat it describesWhat it cannot establish
Controlled adult trial reactionsReported experiences in Anafranil and placebo groups.Your individual likelihood or comparisons with unrelated drug trials.
Other premarketing eventsAdditional events recorded during clinical development.That Anafranil necessarily caused each event.
Voluntary postmarketing reportsReactions reported after approval, from an uncertain population size.A reliable frequency or proof of the cause of your symptom.

What does the label say about sexual and urinary effects?

Sexual and urinary effects receive specific attention in this product’s information. MVBH’s explanatory articles on professional labeling and other medicine documents and the purpose of Medication Guides clarify where different information appears. Neither article is the Anafranil label itself.

The selected Anafranil record reports changes in libido, ejaculation difficulties, and erectile-function problems. It expressly emphasizes male sexual dysfunction in patient counseling. Desire, ejaculation, and erectile function are different aspects of sexual experience; a change in one does not describe all of them. The trial table’s separate male and female categories should not be interpreted to mean that all sexual effects are confined to one group.

Urinary findings include difficulty urinating, urinary retention, changes in frequency, and painful urination. Retention means difficulty emptying the bladder, not simply going more often. These effects are not inevitable, and a listed reaction does not prove the cause of an individual symptom. Sexual or urinary changes are legitimate treatment concerns, not something a person must dismiss as too private to discuss.

Which serious clomipramine safety concerns are identified?

The record identifies seizure risk, antidepressant suicidality warnings, low sodium, and angle-closure eye problems. MVBH’s guides to serious-risk language and professional medicine information explain why these warnings need context rather than being read as predictions.

Seizure risk is expressly identified in the Anafranil patient-counseling section. That warning matters even though this article does not provide an incidence estimate or a way to calculate personal risk. The label connects seizure risk and possible impairment with caution around complex and hazardous activities.

The boxed antidepressant warning and counseling information are relevant to young adults because short-term studies found increased suicidal thinking and behavior in that age group compared with placebo. Separately, the label calls for attention at every age to clinical worsening, suicidal thoughts, and unusual behavioral changes. New or worsening agitation, restlessness, insomnia, impulsivity, or marked mood changes warrant prompt professional attention. This is not a claim that every such change is caused by clomipramine.

The selected Medication Guide and counseling information describe low blood sodium. Possible signs include headache, weakness, unsteadiness, confusion, and difficulties with concentration, thinking, or memory. The guide also identifies eye pain, changes in vision, and swelling or redness around the eye. The counseling section explains that pupil widening can trigger angle-closure glaucoma in susceptible people. These symptoms need timely medical attention, not self-diagnosis from a symptom list.

The FDA contraindications also exclude use during acute recovery after a heart attack and in people with a history of hypersensitivity to Anafranil or other tricyclic antidepressants. These are professional labeling boundaries, not a self-clearance checklist.

For immediate danger or life-threatening symptoms, call 911. For suicide or crisis support, call or text 988, as described by NIMH. MVBH is not an emergency service.

Why do clomipramine interactions need specific review?

Interactions can involve serious combination risks, greater impairment, or changes in drug exposure. MVBH’s explanations of professional medicine information and patient serious-risk guides provide document context. An interaction’s significance depends on the specific medicines involved.

  • MAOIs: The label identifies contraindications involving monoamine oxidase inhibitors used for psychiatric treatment because of increased serotonin-syndrome risk.
  • Linezolid and intravenous methylene blue: Starting Anafranil during treatment with either is also contraindicated because of serotonin-syndrome risk. Interaction concerns therefore extend beyond psychiatric prescriptions.
  • Central nervous system depressants: The counseling section warns that Anafranil may exaggerate responses to alcohol, barbiturates, and other depressants. This is distinct from an interaction that changes blood concentrations.
  • CYP2D6 and CYP1A2 effects: These enzymes participate in processing medicines. Drugs that inhibit them can increase exposure to tricyclic antidepressants, including clomipramine; the label specifically discusses fluvoxamine’s CYP1A2 inhibition.

Exposure means how much medicine the body encounters over time. Another medicine can alter that exposure even when the clomipramine prescription itself has not changed. The FDA interaction and counseling sections describe these concerns and acknowledge that combination risks have not been systematically evaluated. An unlisted combination therefore cannot be assumed safe. These distinctions explain why interaction review is specific, without supplying switching, adjustment, or combination-management instructions.

What is known about older adults and pregnancy?

The label describes important evidence gaps for older adults and pregnancy. MVBH’s articles on understanding medicine documents and interpreting Medication Guide warnings explain the roles of these resources, rather than providing Anafranil-specific population evidence. Missing evidence is not proof of safety or harm.

Studies did not include enough adults aged 65 and older to determine whether their responses differ from younger adults. Although no unusual age-related adverse events were identified in the smaller older population described, that observation does not settle safety for everyone in this age group. The label’s older-adult section specifically notes that older adults may face greater risk of clinically significant low sodium.

For pregnancy, the selected FDA record reports no adequate, well-controlled studies in pregnant women. It describes reported newborn withdrawal symptoms, including jitteriness, tremor, and seizures, after exposure through delivery. Those reports do not predict an individual pregnancy or newborn outcome.

NIMH’s treatment principles emphasize individual needs, medical circumstances, and professional guidance. Product evidence helps inform that discussion but cannot supply a pregnancy recommendation, personal prescription decision, or medicine-change plan.

Source-record identification: This article uses the supplied Anafranil oral-capsule record for application NDA019906, set_id 4074b555-7635-41a9-809d-fae3b3610059, effective_time 20241126. The linked FDA query may return multiple records. These identifiers specify the record discussed; they are not article publication dates or confirmation that it remains the latest labeling.

Written by Tim Francis, SUD Content Specialist. This article is educational and does not diagnose, prescribe, or provide individual treatment instructions.

Frequently asked questions

Does the word antidepressant mean Anafranil is labeled for depression?

No. Tricyclic antidepressant describes clomipramine’s drug class. The selected Anafranil capsule label identifies treatment of obsessions and compulsions in OCD. Those are different kinds of information. The class name does not expand this label’s indications, while an unlisted indication alone does not establish that an individual prescription is inappropriate.

Does the ten-week evidence limit mean treatment must end then?

No. The label states that effectiveness beyond ten weeks had not been systematically evaluated in placebo-controlled trials. That is a limitation of the evidence described, not a treatment deadline or proof that longer treatment cannot help. Individual longer-term usefulness requires professional evaluation rather than a stopping decision based on this article.

Does sleepiness show that clomipramine is helping OCD?

No. Sleepiness is a reported adverse reaction, while OCD benefit was evaluated through measures of obsessions and compulsions. Feeling less alert does not establish symptom improvement. The label separately cautions about impairment of abilities needed for complex or hazardous activities, so alertness and therapeutic benefit should not be treated as the same outcome.

Are sexual and urinary effects inevitable with Anafranil?

No. The label reports these effects but does not predict that every person will experience them. It includes libido changes, ejaculation and erectile-function difficulties, and several urinary complaints. A reported effect is also not proof of the cause of a new symptom. These concerns remain legitimate topics for individualized professional review.

Does this article describe every clomipramine product?

No. It is limited to the supplied Anafranil Capsules USP record for clomipramine hydrochloride taken orally. It does not establish the labeling for every generic version, another formulation, or your own dispensed prescription. It also does not claim that the selected record will remain the latest labeling at publication.

Clomipramine (Anafranil): Related Guides

For more context, explore the full article library, Asenapine: Labeled Uses and Safety for Adults | PHP/IOP MA, Carbamazepine (Equetro): Adult Uses and Safety | PHP/IOP MA.